title: [Observational study on a group of health care workers assigned to antiblastic drugs manipulation in three Sicilian hospitals].
abstract: Neoplastic disease therapy problems, e.g. antiblastic drugs manipulation, is developing. We suggested correlation assessment between the lasting professional workers' exposition of three city hospital and disease development. We selected 43 exposed workers; we gave a questionnaire regarding the modality of activity; then we examined this sample with a protocol including clinical examination and special tests (blood tests, ECG, audiometry and spirometry).
  
  
  RESULTS
  over 55% of the workers reported aspecific complaint related to antiblastic exposure (headache, nausea, vertigo, dermatitis, alopecia, rhino-conjunctivitis, asthenia, parageusia, fauces dryness); we registered, instead, the absence of significant diseases related to antiblastic drugs exposure, because of both environmental and personal prevention, and clinical surveillance co-ordinated by occupational physician.
authors: Sezione di Medicina del Lavoro, Dipartimento di Medicina Clinica e delle Patologie Emergenti, Università degli Studi di Palermo, Italy.
authors: A
authors: A
authors: Provenzani
authors: M G
authors: MG
authors: Verso
authors: G
authors: G
authors: Lacca
authors: P
authors: P
authors: De Marchis
authors: N
authors: N
authors: Mangiapane
authors: D
authors: D
authors: Picciotto
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D006282:Health Personnel / Q000706:statistics & numerical data; D006786:Hospitals, Urban / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D009784:Occupational Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000517:prevention & control*; D016273:Occupational Exposure / Q000009:adverse effects*; D009787:Occupational Medicine / Q000592:standards; D018570:Risk Assessment; D012802:Sicily; D011795:Surveys and Questionnaires; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents